I disagree with your hypothesis.
I wouldn't buy your shares for $25 because I don't have to. I can buy them for roughly sixty cents. But that's not a good analogy because the person who would be spending $25/share gets to market Leronlimab for decades in Cancer, HIV, Nash, Covid/Immune dysfunction, Alzheimers, and a strong handful of other massive disease states, earning back their money plus many more billions along the way.
The board wouldn't (or at least shouldn't) entertain offers much lower than $21 billion because a precedent has been set with the IMMU purchase. I don't disagree that we look cheap if you're staring at the share price, but that's simply not what drives the price of a purchase. If we were valued fairly right now the multiples to get us to $21 billion would look much more reasonable. In the end though, I don't think current share price matters one bit outside of diluting the value of our 200 million shares and making our financial situation less stable than it should or could be. That may be the only thing that allows for a lower valuation than Leronlimab/Cytodyn deserves. But even then it should be much closer to $20/share than .60/share.
I wouldn't buy your shares for $25 because I don't have to. I can buy them for roughly sixty cents. But that's not a good analogy because the person who would be spending $25/share gets to market Leronlimab for decades in Cancer, HIV, Nash, Covid/Immune dysfunction, Alzheimers, and a strong handful of other massive disease states, earning back their money plus many more billions along the way.
The board wouldn't (or at least shouldn't) entertain offers much lower than $21 billion because a precedent has been set with the IMMU purchase. I don't disagree that we look cheap if you're staring at the share price, but that's simply not what drives the price of a purchase. If we were valued fairly right now the multiples to get us to $21 billion would look much more reasonable. In the end though, I don't think current share price matters one bit outside of diluting the value of our 200 million shares and making our financial situation less stable than it should or could be. That may be the only thing that allows for a lower valuation than Leronlimab/Cytodyn deserves. But even then it should be much closer to $20/share than .60/share.
8
